RBR-42nhd6尚未招募2 期
Clinical phase II assessment to assess the effectiveness, safety and tolerability of the peel extract of Passiflora edulis in the reduction of blood pressure in patients with Arterial Hypertension stage I
Conselho Nacional de Desenvolvimento Científico e Tecnológico0 个研究点开始时间: 2019年10月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 60Y（—）
入选标准
- •both sexes; age between 18 and 60 years; distolic arterial pressure between 90 and 99 mmHg in the mean of two measurements with a 5-minute interval in the sitting position on the right brachial artery using a sphygmomanometer; systolic blood pressure lower than 160 mmHg; never had treatment for hypertension; agree to participate in the study with the signature of the TCLE
排除标准
- •secondary hypertension; diagnosis of fasting diabetes or glycemia greater than 120 mg/dL; kidney disease with creatinine> 2 times the upper limit of normal; obesity defined by a body mass index> 30 kg / m2; endocrine diseases (hyperaldosteronism, hypercortisolism, hyperthyroidism, pheochromocytoma); liver disease with ALT or AST> 2 times the upper limit of normal; peptic ulcer in the last 3 months; severe respiratory failure; hemorrhagic disease; Neoplasia and user of intravenous substances; pregnant or nursing women
研究者
相似试验
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.EUCTR2019-001503-20-FRMedica Scientia Innovation Research (MedSIR)100
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001503-20-ITMEDICA SCIENTIA INNOVATION RESEARCH, ARO100
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001503-20-DEMedica Scientia Innovation Research S. L. (MedSIR)100
进行中（未招募）
2 期
A Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapiesCTRI/2013/06/003768ATCO Pharma Limited
招募中
2 期
Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-ACTRI/2019/06/019649ATCO Pharma Ltd